{
  "id": 5082959,
  "title": "Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience",
  "url": "https://urgent.news/2026/09/02/biocytogen-enters-into-non-exclusive-licensing-agreement-with-qilu",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-02T12:04:11.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/biocytogen-enters-into-non-exclusive-licensing-agreement-with-qilu-pharmaceutical-for-a-fully-human-vhh-antibody-to-support-innovative-drug-development-in-neuroscience"
  },
  "original_language": "en",
  "account": null,
  "summary": "BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}